These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 2661281)
21. Insulin treatment improved glucose-induced insulin release in elderly non-insulin-dependent diabetes mellitus, secondary failure to oral hypoglycemic agents. Jap TS; Kwok CF; Won JG; Ho LT Zhonghua Yi Xue Za Zhi (Taipei); 1991 May; 47(5):320-4. PubMed ID: 1649673 [TBL] [Abstract][Full Text] [Related]
22. Beta cell function in long term NIDDM (type 2) patients and its relation to treatment. Snehalatha C; Ramachandran A; Mohan V; Timothy H; Viswanathan M Horm Metab Res; 1986 Jun; 18(6):391-4. PubMed ID: 3525362 [TBL] [Abstract][Full Text] [Related]
23. Short-term effects of continuous subcutaneous insulin infusion treatment on insulin secretion in non-insulin-dependent overweight patients with poor glycaemic control despite maximal oral anti-diabetic treatment. Valensi P; Moura I; Le Magoarou M; Pariès J; Perret G; Attali JR Diabetes Metab; 1997 Feb; 23(1):51-7. PubMed ID: 9059766 [TBL] [Abstract][Full Text] [Related]
24. [Immunologic and insulin secretion markers in non insulin dependent diabetic patients with secondary failure to oral hypoglycemic drugs]. Maiz A; Manrique M; Arteaga A; Acosta AM; Andrade L Rev Med Chil; 1995 Oct; 123(10):1199-203. PubMed ID: 8733310 [TBL] [Abstract][Full Text] [Related]
25. Progressive deterioration of beta-cell function in nonobese type 2 diabetic subjects. Postprandial plasma C-peptide level is an indication of insulin dependency. Prando R; Odetti P; Melga P; Giusti R; Ciuchi E; Cheli V Diabetes Metab; 1996 Jun; 22(3):185-91. PubMed ID: 8697306 [TBL] [Abstract][Full Text] [Related]
26. Oral hypoglycaemic agent failure. Banerjee S; Sinharoy K; Singh AK J Indian Med Assoc; 2002 Jul; 100(7):452-6. PubMed ID: 12674170 [TBL] [Abstract][Full Text] [Related]
27. C-peptide profiles in patients with non-insulin-dependent diabetes mellitus before and during insulin treatment. Lindström T; Arnqvist HJ; Ludvigsson J; von Schenck HH Acta Endocrinol (Copenh); 1992 Jun; 126(6):477-83. PubMed ID: 1642079 [TBL] [Abstract][Full Text] [Related]
28. Beta cell function in insulin-treated non-insulin-dependent diabetic patients. Ramachandran A; Snehalatha C; Mohan V; Rao CA; Viswanathan M Pancreas; 1986; 1(5):411-4. PubMed ID: 3550785 [TBL] [Abstract][Full Text] [Related]
29. The value of islet cell antibody in predicting secondary failure of oral hypoglycaemic agent therapy in Diabetes mellitus. Irvine WJ; Sawers JS; Feek CM; Prescott RJ; Duncan LJ J Clin Lab Immunol; 1979 Apr; 2(1):23-6. PubMed ID: 95802 [TBL] [Abstract][Full Text] [Related]
30. Effects of insulin therapy on non-insulin-dependent diabetics with secondary oral hypoglycemic agent failure. Peng YS; Juang JH Changgeng Yi Xue Za Zhi; 1998 Sep; 21(3):271-6. PubMed ID: 9849007 [TBL] [Abstract][Full Text] [Related]
31. Bedtime intermediate-acting insulin in the treatment of secondary failure to oral hypoglycemic agents. Chuang LM; Lu C; Su RJ; Wu HP; Tai TY; Lin BJ J Formos Med Assoc; 1992 Feb; 91(2):185-9. PubMed ID: 1364216 [TBL] [Abstract][Full Text] [Related]
32. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. Gutniak M; Orskov C; Holst JJ; Ahrén B; Efendic S N Engl J Med; 1992 May; 326(20):1316-22. PubMed ID: 1348845 [TBL] [Abstract][Full Text] [Related]
33. Effect of oral antidiabetic agents on plasma amylin level in patients with non-insulin-dependent diabetes mellitus (type 2). Zapecka-Dubno B; Czyzyk A; Dworak A; Bak MI Arzneimittelforschung; 1999 Apr; 49(4):330-4. PubMed ID: 10337452 [TBL] [Abstract][Full Text] [Related]
34. [Diabetes mellitus in the elderly: a study on its clinical presentation, C-peptide reserve, and immunogenetic markers of insulin dependence]. Seclén Santisteban S; Alvarez Huamán RI; Chantres Antoranz MT; Serrano Ríos M Rev Clin Esp; 1993 Mar; 192(4):162-8. PubMed ID: 8480059 [TBL] [Abstract][Full Text] [Related]
35. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166. Kikuchi M Diabet Med; 1996 Sep; 13(9 Suppl 6):S151-5. PubMed ID: 8894500 [TBL] [Abstract][Full Text] [Related]
36. Combination therapy of glibenclamide and insulin in NIDDM patients with secondary failure to oral drugs. Mohan V; Snehalatha C; Ramachandran A; Viswanathan M J Assoc Physicians India; 1990 Aug; 38(8):537-41. PubMed ID: 2123183 [TBL] [Abstract][Full Text] [Related]
37. C-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment. Takabe M; Matsuda T; Hirota Y; Hashimoto N; Nakamura T; Sakaguchi K; Ogawa W; Seino S Diabetes Res Clin Pract; 2012 Dec; 98(3):e32-5. PubMed ID: 23068961 [TBL] [Abstract][Full Text] [Related]
38. Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients. Willms B; Idowu K; Holst JJ; Creutzfeldt W; Nauck MA Exp Clin Endocrinol Diabetes; 1998; 106(2):103-7. PubMed ID: 9628239 [TBL] [Abstract][Full Text] [Related]
39. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients. van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393 [TBL] [Abstract][Full Text] [Related]
40. Physical Activity Indicators, Metabolic Biomarkers, and Comorbidity in Type 2 Diabetes. Akinci B; Yeldan I; Celik S; Satman I Res Q Exerc Sport; 2019 Dec; 90(4):690-698. PubMed ID: 31479402 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]